Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16153093 | 1.00 | MAPT (0.69) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL1608924 | 1.00 | MAPT (0.69) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL10176166 | 0.98 | MAPT (0.71) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL4835421 | 0.95 | MAPT (0.70) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL11643791 | 0.92 | MAPT (0.78) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL1141920 | 0.89 | MAPT (0.70) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL10870559 | 0.88 | MAPT (0.71) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL9277559 | 0.86 | MAPT (0.61) | MAPTSMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL10982279 | 0.86 | MAPT (0.56) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL10176162 | 0.85 | MAPT (0.69) | MAPTSMN1; SMN2KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102203066-A | Novel dyes and use thereof in imaging members and methods | ZINK IMAGING INC | 2011-09-28 | — | — | CN | disclosed |
| US-20110080458-A1 | NOVEL DYES AND USE THEREOF IN IMAGING MEMBERS AND METHODS | ZINK IMAGING, INC. | 2011-04-07 | — | — | US | disclosed |
| US-7704667-B2 | Dyes and use thereof in imaging members and methods | ZINK IMAGING, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2009097433-A1 | NOVEL DYES AND USE THEREOF IN IMAGING MEMBERS AND METHODS | ZINK IMAGING, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20080187866-A1 | NOVEL DYES AND USE THEREOF IN IMAGING MEMBERS AND METHODS | ZINK IMAGING, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20070224552-A1 | PROCESS FOR THE PREPARATION OF NOVEL DYES FOR USE IN IMAGING MEMBERS | ZINK IMAGING, LLC | 2007-09-27 | — | — | US | disclosed |
| US-7220868-B2 | Process for the preparation of novel dyes for use in imaging members | ZINK IMAGING, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060234143-A1 | Process for the preparation of novel dyes for use in imaging members | ZINK IMAGING, LLC | 2006-10-19 | — | — | US | disclosed |
| US-7008759-B2 | Dyes and use thereof in imaging members and methods | POLAROID CORPORATION (US) | 2006-03-07 | — | — | US | disclosed |
| US-20040191668-A1 | Novel dyes and use thereof in imaging members and methods | ZINK HOLDINGS LLC | 2004-09-30 | — | — | US | disclosed |
| WO-2004078875-A2 | NOVEL DYES AND USE THEREOF IN IMAGING MEMBERS AND METHODS | POLAROID CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080187866-A1 | NOVEL DYES AND USE THEREOF IN IMAGING MEMBERS AND METHODS | CACYBP, KLHDC2, ZKSCAN2 | MAPT 423/4885SMN1; SMN2 4599/4885KDM4E 3727/4885 |
| US-20070224552-A1 | PROCESS FOR THE PREPARATION OF NOVEL DYES FOR USE IN IMAGING MEMBERS | CACYBP, ZKSCAN2, CRYAB | MAPT 280/4885SMN1; SMN2 4420/4885KDM4E 3547/4885 |
| US-20110080458-A1 | NOVEL DYES AND USE THEREOF IN IMAGING MEMBERS AND METHODS | CACYBP, KLHDC2, ZKSCAN2 | MAPT 423/4885SMN1; SMN2 4599/4885KDM4E 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.